ArticleTherapeutic advances in neurological disorders2025

Efgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis.

Yufan Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.